To provide further momentum to the ongoing nationwide vaccination drive, the COVID-19 vaccine Corbevax vaccine will be rolled out by end of November, Biological E Limited said on Monday.
Addressing the reporters briefly after attending an event in Hyderabad, Managing Director of Biological E Limited, Mahima Datla said, "Hyderabad-based Biological E Limited is expecting its Coronavirus vaccine, Corbevax to be rolled out by the end of November. It's our vision, that on the day of the launch, we will supply close to 10 crore doses."
On October 14, Biological E said that it would submit final data on COVID-19 vaccine Corbevax till November end, informed Government sources.
The government was expecting submission of phase 3 data of Biological E by October but after facing delay in procurement of raw materials, Hyderabad - based Biological E is expected to apply for emergency use authorisation of Corbevax by November-end.
The Corbevax is the third made-in-India vaccine against coronavirus, the other two indigenous vaccines are Covaxin and ZyCoV-D.The government earlier announced about the 30 crore doses of Corbevax by December.
The health ministry on Monday informed, "India's COVID-19 vaccination coverage has crossed 102.8 crore (1,02,86,69,053) on Monday. More than 58 lakh (58,87,981) Vaccine doses have been administered till 7 pm today. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)